A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Inclusion Criteria: * Signed written informed consent form voluntarily. * Age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the ICF. * Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. * Expected life expectance ≥ 3 months. * Histologically or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC. * No prior systemic chemotherapy for advanced or metastatic NSCLC. Subjects who have received prior adjuvant chemotherapy or neoadjuvant chemotherapy with curative intent, or definitive chemoradiotherapy for advanced disease, will be eligible provided that progression has occurred \>6 months from last treatment. * At least one measurable tumor lesion per RECIST 1.1 criteria. A lesion previously irradiated will not be considered a target lesion. * Subjects must provide an available tumor tissue sample taken \< 12 months prior to first dose of study treatment. * Subjects must provide wild-type EGFR and ALK reported by tissue-based tests. For subjects without documented wild-type EGFR/ALK, archival or fresh tumor tissues are required for EGFR/ALK assessment prior to enrollment. * Adequate organ function. * Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception. * Nonsterilized males who are sexually active with a female partner of childbearing potential must use highly effective method of contraception from Day 1 and f…